Cargando…
A combination of anti‐PD‐L1 mAb plus Lm‐LLO‐E6 vaccine efficiently suppresses tumor growth and metastasis in HPV‐infected cancers
PD‐1/PD‐L1 immunotherapy is viewed as having clinical benefits in advanced cancers but is effective in only a few patients, suggesting that an efficient combination approach is needed to improve efficacy. Immunohistochemistry analysis indicated that PD‐L1 expression was correlated with the E6 expres...
Autores principales: | Lin, Po‐Lin, Cheng, Ya‐Min, Wu, De‐Wei, Huang, Yu‐Ju, Lin, Hun‐Chi, Chen, Chih‐Yi, Lee, Huei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5603833/ https://www.ncbi.nlm.nih.gov/pubmed/28795532 http://dx.doi.org/10.1002/cam4.1143 |
Ejemplares similares
-
Lm-LLO-Based Immunotherapies and HPV-Associated Disease
por: Wallecha, Anu, et al.
Publicado: (2012) -
Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy
por: Mkrtichyan, Mikayel, et al.
Publicado: (2013) -
Lm-LLO immunotherapies targeting multiple antigens and their impact on different mechanisms in the tumor microenvironment
por: Wallecha, Anu, et al.
Publicado: (2014) -
Listeria monocytogenes (Lm)-LLO immunotherapies reduce the immunosuppressive activity of myeloid-derived suppressor cells and regulatory T cells in the tumor microenvironment
por: Wallecha, Anu, et al.
Publicado: (2013) -
High-dose treatment with ADXS11-001, a listeria monocytogenes (Lm)-listeriolysin O (LLO) immunotherapy, in women with cervical cancer
por: Ghamande, Sharad, et al.
Publicado: (2015)